155 related articles for article (PubMed ID: 23023232)
21. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo.
Zhang J; Zhu JS; Zhou Z; Chen WX; Chen NW
Oncol Rep; 2012 May; 27(5):1511-9. PubMed ID: 22246223
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
23. Roles of microRNA let-7b in papillary thyroid carcinoma by regulating HMGA2.
Li H; Zhao L; Zhang Z; Zhang H; Ding C; Su Z
Tumour Biol; 2017 Oct; 39(10):1010428317719274. PubMed ID: 29025376
[TBL] [Abstract][Full Text] [Related]
24. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
[TBL] [Abstract][Full Text] [Related]
25. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma.
Sun M; Fang S; Li W; Li C; Wang L; Wang F; Wang Y
Cancer Biomark; 2015; 15(1):33-40. PubMed ID: 25524940
[TBL] [Abstract][Full Text] [Related]
26. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
27. Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma.
Czajka AA; Wójcicka A; Kubiak A; Kotlarek M; Bakuła-Zalewska E; Koperski Ł; Wiechno W; Jażdżewski K
PLoS One; 2016; 11(3):e0151968. PubMed ID: 27011326
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
29. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
[TBL] [Abstract][Full Text] [Related]
30. microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.
Lakshmanan A; Wojcicka A; Kotlarek M; Zhang X; Jazdzewski K; Jhiang SM
Endocr Relat Cancer; 2015 Feb; 22(1):11-21. PubMed ID: 25404690
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer.
Geraldo MV; Yamashita AS; Kimura ET
Oncogene; 2012 Apr; 31(15):1910-22. PubMed ID: 21874046
[TBL] [Abstract][Full Text] [Related]
33. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
Nguyen AH; Detty SQ; Agrawal DK
Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
[TBL] [Abstract][Full Text] [Related]
34. Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma.
Guan X; Wang P; Chi J; Zhao S; Wang F
Biochem Biophys Res Commun; 2017 May; 486(4):898-903. PubMed ID: 28342873
[TBL] [Abstract][Full Text] [Related]
35. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle.
Sun J; Shi R; Zhao S; Li X; Lu S; Bu H; Ma X; Su C
J Exp Clin Cancer Res; 2017 Mar; 36(1):40. PubMed ID: 28270228
[TBL] [Abstract][Full Text] [Related]
36. Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a.
Pacifico F; Crescenzi E; Mellone S; Iannetti A; Porrino N; Liguoro D; Moscato F; Grieco M; Formisano S; Leonardi A
J Clin Endocrinol Metab; 2010 Mar; 95(3):1421-30. PubMed ID: 20061417
[TBL] [Abstract][Full Text] [Related]
37. HHV-6A Infection of Papillary Thyroid Cancer Cells Induces Several Effects Related to Cancer Progression.
Mardente S; Romeo MA; Asquino A; Po A; Gilardini Montani MS; Cirone M
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896899
[TBL] [Abstract][Full Text] [Related]
38. Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis.
Aslani F; Schuppe HC; Guazzone VA; Bhushan S; Wahle E; Lochnit G; Lustig L; Meinhardt A; Fijak M
Hum Reprod; 2015 Feb; 30(2):417-31. PubMed ID: 25452436
[TBL] [Abstract][Full Text] [Related]
39. IRAK1, a Target of miR-146b, Reduces Cell Aggressiveness of Human Papillary Thyroid Carcinoma.
Chou CK; Chi SY; Huang CH; Chou FF; Huang CC; Liu RT; Kang HY
J Clin Endocrinol Metab; 2016 Nov; 101(11):4357-4366. PubMed ID: 27533309
[TBL] [Abstract][Full Text] [Related]
40. miR-486-5p inhibits cell growth of papillary thyroid carcinoma by targeting fibrillin-1.
Ma X; Wei J; Zhang L; Deng D; Liu L; Mei X; He X; Tian J
Biomed Pharmacother; 2016 May; 80():220-226. PubMed ID: 27133060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
